TY  - BOOK
AU  - Sullivan, Shannon D
TI  - Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
SN  - 0002-9343
PY  - 2017///
KW  - *Bone Density Conservation Agents/tu [Therapeutic Use]
KW  - *Calcium/tu [Therapeutic Use]
KW  - *Osteoporosis/dt [Drug Therapy]
KW  - *Osteoporotic Fractures/pc [Prevention & Control]
KW  - *Patient Acceptance of Health Care/sn [Statistics & Numerical Data]
KW  - *Vitamin D/tu [Therapeutic Use]
KW  - Aged
KW  - Educational Status
KW  - Female
KW  - Forecasting
KW  - Humans
KW  - Logistic Models
KW  - Longitudinal Studies
KW  - Middle Aged
KW  - Multicenter Studies as Topic
KW  - Osteoporosis/co [Complications]
KW  - Osteoporosis/ep [Epidemiology]
KW  - Osteoporotic Fractures/ep [Epidemiology]
KW  - Social Class
KW  - United States/ep [Epidemiology]
KW  - Women's Health/sn [Statistics & Numerical Data]
KW  - MedStar Washington Hospital Center
KW  - Medicine/Endocrinology
KW  - Journal Article
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - present
N2  - BACKGROUND: Osteoporotic fractures are associated with high morbidity, mortality, and cost; CONCLUSION: Despite well-established treatment guidelines in postmenopausal women with osteoporosis and/or history of fractures, pharmacotherapy use was suboptimal in this study. Initiation of osteoporosis treatment after fragility fracture may represent an opportunity to improve later outcomes in these high-risk women. Specific attention needs to be paid to increasing treatment among women with fragility fractures, obesity, current tobacco use, history of arthritis or of black race/ethnicity; Copyright (c) 2017. Published by Elsevier Inc; METHODS: We performed a post hoc analysis of the Women's Health Initiative (WHI) clinical trials (CT) data to assess osteoporosis treatment and identify participant characteristics associated with utilization of osteoporosis medication(s) after new diagnoses of osteoporosis and/or fracture. Information from visits prior to and immediately subsequent to the first fracture event or osteoporosis diagnosis were evaluated for medication use. A full logistic regression model was used to identify factors predictive of osteoporosis medication use after a fracture and/or a diagnosis of osteoporosis; RESULTS: The median length of follow-up from enrollment to the last WHI clinic visit for the study cohort was 13.9 years. Among the 13,990 women who reported new diagnoses of osteoporosis and/or fracture between enrollment and their final WHI visit, and also had medication data available, 21.6% reported taking an osteoporosis medication other than estrogen. Higher daily calcium intake, diagnosis of osteoporosis alone or both osteoporosis and fracture (compared to diagnosis of fracture alone), Asian or Pacific Islander race/ethnicity (compared to white/Caucasian), higher income, and hormone therapy use (past or present) were associated with significantly higher likelihood of osteoporosis pharmacotherapy. Women with black/African-American race/ethnicity (compared to white/Caucasian), BMI > 30 (compared to BMI of 18.5-24.9), current tobacco use (compared to past use or lifetime nonusers), and history of arthritis were less likely to use osteoporosis treatment
UR  - https://dx.doi.org/10.1016/j.amjmed.2017.02.042
ER  -